tiprankstipranks
Tyra Bioscience (TYRA)
NASDAQ:TYRA
US Market
TYRA
Tyra Bioscience
RESEARCH TOOLSreports
Want to see TYRA full AI Analyst Report?

Tyra Bioscience (TYRA) Stock Forecast & Price Target

144 Followers
See the Price Targets and Ratings of:

TYRA Analyst Ratings

Strong Buy
11Ratings
Strong Buy
10 Buy
1 Hold
0 Sell
Based on 11 analysts giving stock ratings to
Tyra
Bioscience
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

TYRA Stock 12 Month Forecast

Average Price Target

$49.25
▲(60.79% Upside)
Based on 11 Wall Street analysts offering 12 month price targets for Tyra Bioscience in the last 3 months. The average price target is $49.25 with a high forecast of $59.00 and a low forecast of $39.00. The average price target represents a 60.79% change from the last price of $30.63.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"9":"$9","60":"$60","21.75":"$21.8","34.5":"$34.5","47.25":"$47.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":59,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$59.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":49.25,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$49.25</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":39,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$39.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[9,21.75,34.5,47.25,60],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,31.88,33.966153846153844,36.05230769230769,38.138461538461534,40.22461538461538,42.310769230769225,44.39692307692307,46.48307692307692,48.56923076923077,50.65538461538461,52.741538461538454,54.8276923076923,56.91384615384615,{"y":59,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,31.88,33.216153846153844,34.55230769230769,35.88846153846154,37.22461538461538,38.56076923076923,39.89692307692307,41.23307692307692,42.56923076923077,43.90538461538462,45.24153846153846,46.57769230769231,47.91384615384615,{"y":49.25,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,31.88,32.427692307692304,32.97538461538461,33.52307692307692,34.07076923076923,34.61846153846154,35.16615384615385,35.713846153846156,36.261538461538464,36.809230769230766,37.356923076923074,37.90461538461538,38.45230769230769,{"y":39,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":10.37,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.53,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.42,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.84,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.81,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.29,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31.02,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":32.52,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":38.28,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":34.04,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":30.39,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29.41,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31.88,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$59.00Average Price Target$49.25Lowest Price Target$39.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Canaccord Genuity Analyst forecast on TYRA
John Newman
Canaccord Genuity
Canaccord Genuity
$50
Buy
63.24%
Upside
Reiterated
08/12/26
John Newman Maintains Buy Rating on Tyra with Unchanged $50 Price Target, Citing Dabogratinib’s Strong Growth Potential and Safety Profile in Achondroplasia
Bank of America Securities Analyst forecast on TYRA
Jason Zemansky
Bank of America Securities
Bank of America Securities
$42→$39
Buy
27.33%
Upside
Reiterated
08/11/26
Tyra Bioscience (TYRA) Gets a Buy from Bank of America Securities
William Blair Analyst forecast on TYRA
Sami Corwin
William Blair
William Blair
―
Buy
―
Reiterated
08/05/26
Analysts Are Bullish on Top Healthcare Stocks: Alphatec Holdings (ATEC), Tyra Bioscience (TYRA)
H.C. Wainwright Analyst forecast on TYRA
Mitchell Kapoor
H.C. Wainwright
H.C. Wainwright
$45
Buy
46.91%
Upside
Reiterated
08/05/26
Analyst Reiterates Buy on Tyra, Maintaining $45 Price Target Ahead of Key SURF302 Phase 2 Readout
Wedbush Analyst forecast on TYRA
Robert Driscoll
Wedbush
Wedbush
$53
Buy
73.03%
Upside
Reiterated
08/05/26
Tyra Bioscience (TYRA) Gets a Buy from Wedbush
Jefferies Analyst forecast on TYRA
Maury Raycroft
Jefferies
Jefferies
$44→$42
Buy
37.12%
Upside
Reiterated
08/05/26
Tyra Biosciences price target lowered to $42 from $44 at JefferiesTyra Biosciences price target lowered to $42 from $44 at Jefferies
JonesTrading Analyst forecast on TYRA
Boris Peaker
JonesTrading
JonesTrading
$56
Buy
82.83%
Upside
Reiterated
08/04/26
Tyra Biosciences: Boris Peaker Reaffirms Buy Rating with $56 Price Target on Strength of FGFR3 Pipeline and Upcoming SURF-302/BEACH-301 Data
Oppenheimer Analyst forecast on TYRA
Mazahir Alimohamed
Oppenheimer
Oppenheimer
$50
Buy
63.24%
Upside
Reiterated
07/31/26
Tyra Bioscience (TYRA) Gets a Buy from Oppenheimer
Raymond James Analyst forecast on TYRA
Christopher Raymond
Raymond James
Raymond James
―
Buy
―
Reiterated
07/17/26
Analysts Are Bullish on These Healthcare Stocks: Tyra Bioscience (TYRA), Eli Lilly & Co (LLY)
Barclays Analyst forecast on TYRA
Eliana Merle
Barclays
Barclays
$59
Buy
92.62%
Upside
Reiterated
06/03/26
Barclays Keeps Their Buy Rating on Tyra Bioscience (TYRA)
Wolfe Research Analyst forecast on TYRA
Kalpit Patel
Wolfe Research
Wolfe Research
―
Hold
―
Initiated
05/19/26
Tyra Biosciences initiated with a Peer Perform at Wolfe ResearchTyra Biosciences initiated with a Peer Perform at Wolfe Research
TD Cowen Analyst forecast on TYRA
Tyler Van Buren
TD Cowen
TD Cowen
―
Buy
―
Reiterated
05/13/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: West Pharmaceutical Services (NYSE: WST), CalciMedica (NASDAQ: CALC) and Tyra Bioscience (NASDAQ: TYRA)
Guggenheim Analyst forecast on TYRA
Bradley Canino
Guggenheim
Guggenheim
$54
Buy
76.30%
Upside
Initiated
04/15/26
Tyra Biosciences initiated with a Buy at GuggenheimTyra Biosciences initiated with a Buy at Guggenheim
Piper Sandler Analyst forecast on TYRA
Allison Bratzel
Piper Sandler
Piper Sandler
$42→$56
Buy
82.83%
Upside
Reiterated
03/20/26
Tyra Bioscience (TYRA) Receives a Buy from Piper Sandler
Cantor Fitzgerald Analyst forecast on TYRA
Li Watsek
Cantor Fitzgerald
Cantor Fitzgerald
―
Buy
―
Reiterated
03/04/26
Analysts Offer Insights on Healthcare Companies: Alcon (NYSE: ALC) and Tyra Bioscience (NASDAQ: TYRA)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Canaccord Genuity Analyst forecast on TYRA
John Newman
Canaccord Genuity
Canaccord Genuity
$50
Buy
63.24%
Upside
Reiterated
08/12/26
John Newman Maintains Buy Rating on Tyra with Unchanged $50 Price Target, Citing Dabogratinib’s Strong Growth Potential and Safety Profile in Achondroplasia
Bank of America Securities Analyst forecast on TYRA
Jason Zemansky
Bank of America Securities
Bank of America Securities
$42→$39
Buy
27.33%
Upside
Reiterated
08/11/26
Tyra Bioscience (TYRA) Gets a Buy from Bank of America Securities
William Blair Analyst forecast on TYRA
Sami Corwin
William Blair
William Blair
―
Buy
―
Reiterated
08/05/26
Analysts Are Bullish on Top Healthcare Stocks: Alphatec Holdings (ATEC), Tyra Bioscience (TYRA)
H.C. Wainwright Analyst forecast on TYRA
Mitchell Kapoor
H.C. Wainwright
H.C. Wainwright
$45
Buy
46.91%
Upside
Reiterated
08/05/26
Analyst Reiterates Buy on Tyra, Maintaining $45 Price Target Ahead of Key SURF302 Phase 2 Readout
Wedbush Analyst forecast on TYRA
Robert Driscoll
Wedbush
Wedbush
$53
Buy
73.03%
Upside
Reiterated
08/05/26
Tyra Bioscience (TYRA) Gets a Buy from Wedbush
Jefferies Analyst forecast on TYRA
Maury Raycroft
Jefferies
Jefferies
$44→$42
Buy
37.12%
Upside
Reiterated
08/05/26
Tyra Biosciences price target lowered to $42 from $44 at JefferiesTyra Biosciences price target lowered to $42 from $44 at Jefferies
JonesTrading Analyst forecast on TYRA
Boris Peaker
JonesTrading
JonesTrading
$56
Buy
82.83%
Upside
Reiterated
08/04/26
Tyra Biosciences: Boris Peaker Reaffirms Buy Rating with $56 Price Target on Strength of FGFR3 Pipeline and Upcoming SURF-302/BEACH-301 Data
Oppenheimer Analyst forecast on TYRA
Mazahir Alimohamed
Oppenheimer
Oppenheimer
$50
Buy
63.24%
Upside
Reiterated
07/31/26
Tyra Bioscience (TYRA) Gets a Buy from Oppenheimer
Raymond James Analyst forecast on TYRA
Christopher Raymond
Raymond James
Raymond James
―
Buy
―
Reiterated
07/17/26
Analysts Are Bullish on These Healthcare Stocks: Tyra Bioscience (TYRA), Eli Lilly & Co (LLY)
Barclays Analyst forecast on TYRA
Eliana Merle
Barclays
Barclays
$59
Buy
92.62%
Upside
Reiterated
06/03/26
Barclays Keeps Their Buy Rating on Tyra Bioscience (TYRA)
Wolfe Research Analyst forecast on TYRA
Kalpit Patel
Wolfe Research
Wolfe Research
―
Hold
―
Initiated
05/19/26
Tyra Biosciences initiated with a Peer Perform at Wolfe ResearchTyra Biosciences initiated with a Peer Perform at Wolfe Research
TD Cowen Analyst forecast on TYRA
Tyler Van Buren
TD Cowen
TD Cowen
―
Buy
―
Reiterated
05/13/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: West Pharmaceutical Services (NYSE: WST), CalciMedica (NASDAQ: CALC) and Tyra Bioscience (NASDAQ: TYRA)
Guggenheim Analyst forecast on TYRA
Bradley Canino
Guggenheim
Guggenheim
$54
Buy
76.30%
Upside
Initiated
04/15/26
Tyra Biosciences initiated with a Buy at GuggenheimTyra Biosciences initiated with a Buy at Guggenheim
Piper Sandler Analyst forecast on TYRA
Allison Bratzel
Piper Sandler
Piper Sandler
$42→$56
Buy
82.83%
Upside
Reiterated
03/20/26
Tyra Bioscience (TYRA) Receives a Buy from Piper Sandler
Cantor Fitzgerald Analyst forecast on TYRA
Li Watsek
Cantor Fitzgerald
Cantor Fitzgerald
―
Buy
―
Reiterated
03/04/26
Analysts Offer Insights on Healthcare Companies: Alcon (NYSE: ALC) and Tyra Bioscience (NASDAQ: TYRA)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
BTSGBrightSpring Health Services, Inc.
AMLXAmylyx Pharmaceuticals Inc
IMMXImmix Biopharma
JBIOJade Biosciences
GHRSGH Research
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Tyra Bioscience

3 Months
Mitchell KapoorH.C. Wainwright
Success Rate
17/29 ratings generated profit
59%
Average Return
+11.92%
Copying Mitchell Kapoor's trades and holding each position for 3 Months would result in 58.62% of your transactions generating a profit, with an average return of +11.92% per trade.
1 Year
Mitchell KapoorH.C. Wainwright
Success Rate
17/29 ratings generated profit
59%
Average Return
+52.31%
Copying Mitchell Kapoor's trades and holding each position for 1 Year would result in 58.62% of your transactions generating a profit, with an average return of +52.31% per trade.
2 Years
Tyler Van BurenTD Cowen
Success Rate
13/16 ratings generated profit
81%
Average Return
+68.39%
Copying Tyler Van Buren's trades and holding each position for 2 Years would result in 81.25% of your transactions generating a profit, with an average return of +68.39% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

TYRA Analyst Recommendation Trends

Rating
Apr 26
May 26
Jun 26
Jul 26
Aug 26
Strong Buy
12
7
12
15
20
Buy
15
20
16
13
3
Hold
0
1
1
1
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
27
28
29
29
23
In the current month, TYRA has received 23 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. TYRA average Analyst price target in the past 3 months is 49.25.
Each month's total comprises the sum of three months' worth of ratings.

TYRA Financial Forecast

TYRA Earnings Forecast

Next quarter’s earnings estimate for TYRA is -$0.69 with a range of -$0.76 to -$0.59. The previous quarter’s EPS was -$0.69. TYRA beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year TYRA has Performed in-line its overall industry.
Next quarter’s earnings estimate for TYRA is -$0.69 with a range of -$0.76 to -$0.59. The previous quarter’s EPS was -$0.69. TYRA beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year TYRA has Performed in-line its overall industry.
No data currently available

TYRA Sales Forecast

Next quarter’s sales forecast for TYRA is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. TYRA beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year TYRA has Performed in-line its overall industry.
Next quarter’s sales forecast for TYRA is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. TYRA beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year TYRA has Performed in-line its overall industry.

TYRA Stock Forecast FAQ

What is TYRA’s average 12-month price target, according to analysts?
Based on analyst ratings, Tyra Bioscience’s 12-month average price target is 49.25.
    What is TYRA’s upside potential, based on the analysts’ average price target?
    Tyra Bioscience has 60.79% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is TYRA a Buy, Sell or Hold?
          Tyra Bioscience has a consensus rating of Strong Buy which is based on 10 buy ratings, 1 hold ratings and 0 sell ratings.
            What is Tyra Bioscience’s price target?
            The average price target for Tyra Bioscience is 49.25. This is based on 11 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $59.00 ,the lowest forecast is $39.00. The average price target represents 60.79% Increase from the current price of $30.63.
              What do analysts say about Tyra Bioscience?
              Tyra Bioscience’s analyst rating consensus is a Strong Buy. This is based on the ratings of 11 Wall Streets Analysts.
                How can I buy shares of TYRA?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.